These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

302 related articles for article (PubMed ID: 32333502)

  • 1. Darolutamide antagonizes androgen signaling by blocking enhancer and super-enhancer activation.
    Baumgart SJ; Nevedomskaya E; Lesche R; Newman R; Mumberg D; Haendler B
    Mol Oncol; 2020 Sep; 14(9):2022-2039. PubMed ID: 32333502
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Crosstalk between androgen and pro-inflammatory signaling remodels androgen receptor and NF-κB cistrome to reprogram the prostate cancer cell transcriptome.
    Malinen M; Niskanen EA; Kaikkonen MU; Palvimo JJ
    Nucleic Acids Res; 2017 Jan; 45(2):619-630. PubMed ID: 27672034
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Moving Towards Precision Urologic Oncology: Targeting Enzalutamide-resistant Prostate Cancer and Mutated Forms of the Androgen Receptor Using the Novel Inhibitor Darolutamide (ODM-201).
    Borgmann H; Lallous N; Ozistanbullu D; Beraldi E; Paul N; Dalal K; Fazli L; Haferkamp A; Lejeune P; Cherkasov A; Gleave ME
    Eur Urol; 2018 Jan; 73(1):4-8. PubMed ID: 28851578
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Dissecting transcription of the 8q24-MYC locus in prostate cancer recognizes the equilibration between androgen receptor direct and indirect dual-functions.
    Guo J; Wei Z; Jia T; Wang L; Nama N; Liang J; Liao X; Liu X; Gao Y; Liu X; Wang K; Fu B; Chen SS
    J Transl Med; 2023 Oct; 21(1):716. PubMed ID: 37828515
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Three-tiered role of the pioneer factor GATA2 in promoting androgen-dependent gene expression in prostate cancer.
    Wu D; Sunkel B; Chen Z; Liu X; Ye Z; Li Q; Grenade C; Ke J; Zhang C; Chen H; Nephew KP; Huang TH; Liu Z; Jin VX; Wang Q
    Nucleic Acids Res; 2014 Apr; 42(6):3607-22. PubMed ID: 24423874
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Aberrant activation of super enhancer and choline metabolism drive antiandrogen therapy resistance in prostate cancer.
    Wen S; He Y; Wang L; Zhang J; Quan C; Niu Y; Huang H
    Oncogene; 2020 Oct; 39(42):6556-6571. PubMed ID: 32917955
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Androgen receptor and MYC equilibration centralizes on developmental super-enhancer.
    Guo H; Wu Y; Nouri M; Spisak S; Russo JW; Sowalsky AG; Pomerantz MM; Wei Z; Korthauer K; Seo JH; Wang L; Arai S; Freedman ML; He HH; Chen S; Balk SP
    Nat Commun; 2021 Dec; 12(1):7308. PubMed ID: 34911936
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Cooperativity and equilibrium with FOXA1 define the androgen receptor transcriptional program.
    Jin HJ; Zhao JC; Wu L; Kim J; Yu J
    Nat Commun; 2014 May; 5():3972. PubMed ID: 24875621
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Androgen receptor transcriptionally regulates semaphorin 3C in a GATA2-dependent manner.
    Tam KJ; Dalal K; Hsing M; Cheng CW; Khosravi S; Yenki P; Tse C; Peacock JW; Sharma A; Chiang YT; Wang Y; Cherkasov A; Rennie PS; Gleave ME; Ong CJ
    Oncotarget; 2017 Feb; 8(6):9617-9633. PubMed ID: 28038451
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Integrated analysis identifies a class of androgen-responsive genes regulated by short combinatorial long-range mechanism facilitated by CTCF.
    Taslim C; Chen Z; Huang K; Huang TH; Wang Q; Lin S
    Nucleic Acids Res; 2012 Jun; 40(11):4754-64. PubMed ID: 22344698
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Selective targeting of PARP-2 inhibits androgen receptor signaling and prostate cancer growth through disruption of FOXA1 function.
    Gui B; Gui F; Takai T; Feng C; Bai X; Fazli L; Dong X; Liu S; Zhang X; Zhang W; Kibel AS; Jia L
    Proc Natl Acad Sci U S A; 2019 Jul; 116(29):14573-14582. PubMed ID: 31266892
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Darolutamide is a potent androgen receptor antagonist with strong efficacy in prostate cancer models.
    Sugawara T; Baumgart SJ; Nevedomskaya E; Reichert K; Steuber H; Lejeune P; Mumberg D; Haendler B
    Int J Cancer; 2019 Sep; 145(5):1382-1394. PubMed ID: 30828788
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Dual role of FoxA1 in androgen receptor binding to chromatin, androgen signalling and prostate cancer.
    Sahu B; Laakso M; Ovaska K; Mirtti T; Lundin J; Rannikko A; Sankila A; Turunen JP; Lundin M; Konsti J; Vesterinen T; Nordling S; Kallioniemi O; Hautaniemi S; Jänne OA
    EMBO J; 2011 Sep; 30(19):3962-76. PubMed ID: 21915096
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Activated Cdc42-associated kinase Ack1 promotes prostate cancer progression via androgen receptor tyrosine phosphorylation.
    Mahajan NP; Liu Y; Majumder S; Warren MR; Parker CE; Mohler JL; Earp HS; Whang YE
    Proc Natl Acad Sci U S A; 2007 May; 104(20):8438-43. PubMed ID: 17494760
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Exploitation of Castration-Resistant Prostate Cancer Transcription Factor Dependencies by the Novel BET Inhibitor ABBV-075.
    Faivre EJ; Wilcox D; Lin X; Hessler P; Torrent M; He W; Uziel T; Albert DH; McDaniel K; Kati W; Shen Y
    Mol Cancer Res; 2017 Jan; 15(1):35-44. PubMed ID: 27707886
    [TBL] [Abstract][Full Text] [Related]  

  • 16. A natural androgen receptor antagonist induces cellular senescence in prostate cancer cells.
    Hessenkemper W; Roediger J; Bartsch S; Houtsmuller AB; van Royen ME; Petersen I; Grimm MO; Baniahmad A
    Mol Endocrinol; 2014 Nov; 28(11):1831-40. PubMed ID: 25203674
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Persistent androgen receptor-mediated transcription in castration-resistant prostate cancer under androgen-deprived conditions.
    Decker KF; Zheng D; He Y; Bowman T; Edwards JR; Jia L
    Nucleic Acids Res; 2012 Nov; 40(21):10765-79. PubMed ID: 23019221
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Androgen receptor regulates a distinct transcription program in androgen-independent prostate cancer.
    Wang Q; Li W; Zhang Y; Yuan X; Xu K; Yu J; Chen Z; Beroukhim R; Wang H; Lupien M; Wu T; Regan MM; Meyer CA; Carroll JS; Manrai AK; Jänne OA; Balk SP; Mehra R; Han B; Chinnaiyan AM; Rubin MA; True L; Fiorentino M; Fiore C; Loda M; Kantoff PW; Liu XS; Brown M
    Cell; 2009 Jul; 138(2):245-56. PubMed ID: 19632176
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Dynamic nucleosome-depleted regions at androgen receptor enhancers in the absence of ligand in prostate cancer cells.
    Andreu-Vieyra C; Lai J; Berman BP; Frenkel B; Jia L; Jones PA; Coetzee GA
    Mol Cell Biol; 2011 Dec; 31(23):4648-62. PubMed ID: 21969603
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Androgen receptor and its splice variant, AR-V7, differentially regulate FOXA1 sensitive genes in LNCaP prostate cancer cells.
    Krause WC; Shafi AA; Nakka M; Weigel NL
    Int J Biochem Cell Biol; 2014 Sep; 54():49-59. PubMed ID: 25008967
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 16.